The role of immune checkpoint blockade in acute myeloid leukemia
Immune checkpoint inhibition (ICI) has emerged as a therapeutic option for acute myeloid leukemia (AML) for patients that suffer from relapsed or high-risk disease, or patients ineligible for standard therapy. We aimed to study ICI as monotherapy and/or combined therapy (with chemotherapy (QT), for...
| Autor principal: | |
|---|---|
| Outros Autores: | , |
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
2022
|
| Assuntos: | |
| Texto completo: | http://hdl.handle.net/10400.26/41902 |
| País: | Portugal |
| Oai: | oai:comum.rcaap.pt:10400.26/41902 |